Ribogenics, a biotechnology company developing RNA-targeted small molecule therapeutics, has strengthened its leadership with the appointment of a Director of Discovery Research.
The role leads discovery programs across oncology and neurodegenerative diseases, accelerating the development of splice-modulating therapies.
This strategic hire enhances Ribogenics’ in-house capability to translate RNA biology into precision medicines, advancing its mission to deliver next-generation treatments for complex diseases.
